1-11 of 11
Maureen F. Zakowski
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

Helena A. Yu, Maria E. Arcila, Natasha Rekhtman, Camelia S. Sima, Maureen F. Zakowski, William Pao, Mark G. Kris, Vincent A. Miller, Marc Ladanyi, Gregory J. Riely
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (8): 2240–2247.
https://doi.org/10.1158/1078-0432.CCR-12-2246
Published: 15 April 2013
View article titled, Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with <em>EGFR</em>-Mutant Lung Cancers
Open the PDF for Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with <em>EGFR</em>-Mutant Lung Cancers in another window
Journal Articles

Identification of KIF5B-RET and GOPC-ROS1 Fusions in Lung Adenocarcinomas through a Comprehensive mRNA-Based Screen for Tyrosine Kinase Fusions

Yoshiyuki Suehara, Maria Arcila, Lu Wang, Adnan Hasanovic, Daphne Ang, Tatsuo Ito, Yuki Kimura, Alexander Drilon, Udayan Guha, Valerie Rusch, Mark G. Kris, Maureen F. Zakowski, Naiyer Rizvi, Raya Khanin, Marc Ladanyi
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (24): 6599–6608.
https://doi.org/10.1158/1078-0432.CCR-12-0838
Published: 16 December 2012
View article titled, Identification of <em>KIF5B-RET</em> and <em>GOPC-ROS1</em> Fusions in Lung Adenocarcinomas through a Comprehensive mRNA-Based Screen for Tyrosine Kinase Fusions
Open the PDF for Identification of <em>KIF5B-RET</em> and <em>GOPC-ROS1</em> Fusions in Lung Adenocarcinomas through a Comprehensive mRNA-Based Screen for Tyrosine Kinase Fusions in another window
Includes: Supplementary data
Journal Articles

Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers

Snjezana Dogan, Ronglai Shen, Daphne C. Ang, Melissa L. Johnson, Sandra P. D'Angelo, Paul K. Paik, Edyta B. Brzostowski, Gregory J. Riely, Mark G. Kris, Maureen F. Zakowski, Marc Ladanyi
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (22): 6169–6177.
https://doi.org/10.1158/1078-0432.CCR-11-3265
Published: 14 November 2012
View article titled, Molecular Epidemiology of <em>EGFR</em> and <em>KRAS</em> Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related <em>KRAS</em>-Mutant Cancers
Open the PDF for Molecular Epidemiology of <em>EGFR</em> and <em>KRAS</em> Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related <em>KRAS</em>-Mutant Cancers in another window
Includes: Supplementary data
Journal Articles

Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung Adenocarcinomas

Maria E. Arcila, Jamie E. Chaft, Khedoudja Nafa, Sinchita Roy-Chowdhuri, Christopher Lau, Michael Zaidinski, Paul K. Paik, Maureen F. Zakowski, Mark G. Kris, Marc Ladanyi
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (18): 4910–4918.
https://doi.org/10.1158/1078-0432.CCR-12-0912
Published: 16 September 2012
View article titled, Prevalence, Clinicopathologic Associations, and Molecular Spectrum of <em>ERBB2</em> (<em>HER2</em>) Tyrosine Kinase Mutations in Lung Adenocarcinomas
Open the PDF for Prevalence, Clinicopathologic Associations, and Molecular Spectrum of <em>ERBB2</em> (<em>HER2</em>) Tyrosine Kinase Mutations in Lung Adenocarcinomas in another window
Includes: Supplementary data
Journal Articles

Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR/KRAS and Presence of PIK3CA/AKT1 Mutations

Natasha Rekhtman, Paul K. Paik, Maria E. Arcila, Laura J. Tafe, Geoffrey R. Oxnard, Andre L. Moreira, William D. Travis, Maureen F. Zakowski, Mark G. Kris, Marc Ladanyi
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (4): 1167–1176.
https://doi.org/10.1158/1078-0432.CCR-11-2109
Published: 14 February 2012
View article titled, Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of <em>EGFR</em>/<em>KRA</em>S and Presence of <em>PIK3CA</em>/<em>AKT1</em> Mutations
Open the PDF for Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of <em>EGFR</em>/<em>KRA</em>S and Presence of <em>PIK3CA</em>/<em>AKT1</em> Mutations in another window
Includes: Supplementary data
Journal Articles

Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay

Maria E. Arcila, Geoffrey R. Oxnard, Khedoudja Nafa, Gregory J. Riely, Stephen B. Solomon, Maureen F. Zakowski, Mark G. Kris, William Pao, Vincent A. Miller, Marc Ladanyi
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (5): 1169–1180.
https://doi.org/10.1158/1078-0432.CCR-10-2277
Published: 01 March 2011
View article titled, Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay
Open the PDF for Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay in another window
Includes: Supplementary data
Journal Articles

Comprehensive Genomic Analysis Reveals Clinically Relevant Molecular Distinctions between Thymic Carcinomas and Thymomas

Nicolas Girard, Ronglai Shen, Tianhua Guo, Maureen F. Zakowski, Adriana Heguy, Gregory J. Riely, James Huang, Christopher Lau, Alex E. Lash, Marc Ladanyi, Agnes Viale, Cristina R. Antonescu, William D. Travis, Valerie W. Rusch, Mark G. Kris, William Pao
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (22): 6790–6799.
https://doi.org/10.1158/1078-0432.CCR-09-0644
Published: 11 November 2009
View article titled, Comprehensive Genomic Analysis Reveals Clinically Relevant Molecular Distinctions between Thymic Carcinomas and Thymomas
Open the PDF for Comprehensive Genomic Analysis Reveals Clinically Relevant Molecular Distinctions between Thymic Carcinomas and Thymomas in another window
Includes: Supplementary data
Journal Articles

Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors

Marissa N. Balak, Yixuan Gong, Gregory J. Riely, Romel Somwar, Allan R. Li, Maureen F. Zakowski, Anne Chiang, Guangli Yang, Ouathek Ouerfelli, Mark G. Kris, Marc Ladanyi, Vincent A. Miller, William Pao
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (21): 6494–6501.
https://doi.org/10.1158/1078-0432.CCR-06-1570
Published: 03 November 2006
View article titled, Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors
Open the PDF for Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors in another window
Includes: Supplementary data
Journal Articles

Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib

Gregory J. Riely, William Pao, DuyKhanh Pham, Allan R. Li, Naiyer Rizvi, Ennapadam S. Venkatraman, Maureen F. Zakowski, Mark G. Kris, Marc Ladanyi, Vincent A. Miller
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (3): 839–844.
https://doi.org/10.1158/1078-0432.CCR-05-1846
Published: 07 February 2006
View article titled, Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib
Open the PDF for Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib in another window
Journal Articles

Homozygous Deletion of CDKN2A and Codeletion of the Methylthioadenosine Phosphorylase Gene in the Majority of Pleural Mesotheliomas

Peter B. Illei, Valerie W. Rusch, Maureen F. Zakowski, Marc Ladanyi
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (6): 2108–2113.
Published: 01 June 2003
View article titled, Homozygous Deletion of <em>CDKN2A</em> and Codeletion of the Methylthioadenosine Phosphorylase Gene in the Majority of Pleural Mesotheliomas
Open the PDF for Homozygous Deletion of <em>CDKN2A</em> and Codeletion of the Methylthioadenosine Phosphorylase Gene in the Majority of Pleural Mesotheliomas in another window
Journal Articles

Efficacy of Cytotoxic Agents against Human Tumor Xenografts Is Markedly Enhanced By Coadministration of ZD1839 (Iressa), an Inhibitor of EGFR Tyrosine Kinase

Francis M. Sirotnak, Maureen F. Zakowski, Vincent A. Miller, Howard I. Scher, Mark G. Kris
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (12): 4885–4892.
Published: 01 December 2000
View article titled, Efficacy of Cytotoxic Agents against Human Tumor Xenografts Is Markedly Enhanced By Coadministration of ZD1839 (Iressa), an Inhibitor of EGFR Tyrosine Kinase
Open the PDF for Efficacy of Cytotoxic Agents against Human Tumor Xenografts Is Markedly Enhanced By Coadministration of ZD1839 (Iressa), an Inhibitor of EGFR Tyrosine Kinase in another window